Is Adeshwar Meditex overvalued or undervalued?

As of 20 June 2025, Adeshwar Meditex has moved from a risky to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 12.72, an EV to EBITDA of 8.94, and a ROCE of 8.12%. In comparison to its peers, Adeshwar Meditex's valuation metrics appear reasonable; for instance, Poly Medicure has a significantly higher PE ratio of 61.82, while BPL, another peer, has a lower PE of 6.71 but is also categorized as fair.
Despite the fair valuation, Adeshwar Meditex has underperformed relative to the Sensex, with a year-to-date return of -29.81% compared to the Sensex's 5.46%. This underperformance, combined with the current valuation metrics, suggests that while the company is fairly valued, it may face challenges in improving its market position in the near term.